Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 5/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12487435 | 1.00 | SCN4A (0.40) | SCN4ATACR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL6504637 | 1.00 | SCN4A (0.40) | SCN4ATACR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL22502109 | 0.85 | SCN4A (0.49) | SCN4ATACR1 | |
| SCHEMBL366662 | 0.85 | SCN4A (0.49) | SCN4ATACR1 | |
| SCHEMBL1850702 | 0.85 | SCN4A (0.49) | SCN4ATACR1 | |
| SCHEMBL12493506 | 0.84 | ADRB2 (0.39) | SCN4AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL6221097 | 0.83 | RIPK1 (0.51) | — | |
| SCHEMBL14686246 | 0.83 | IDO1 (0.40) | — | |
| SCHEMBL6598638 | 0.83 | GABBR2 (0.39) | — | |
| SCHEMBL14686247 | 0.83 | IDO1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683705-B1 | DI- AND TRI-SUBSTITUTED OXATHIAZINE DERIVATES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICINE AND DRUG CONTAINING SAID DERIVATIVES AND USE THEREOF | SANOFI SA (FR) | 2015-04-22 | — | — | EP | disclosed |
| US-6953797-B2 | Use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-10-11 | — | — | US | disclosed |
| EP-1263718-B1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030073685-A1 | Novel use of phenylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | US | disclosed |
| EP-1263718-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001062721-A1 | NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073685-A1 | Novel use of phenylheteroalkylamine derivatives | CYP1A1, CYP1A2, CYP2E1 | SCN4A 1664/4885TACR1 851/4885GRIN2D 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.